UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 4, pp. 354 - 369
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Viral Load | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Sofosbuvir - therapeutic use | Drug Administration Schedule | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Genotype | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Drug Combinations | Antiviral agents | Care and treatment | Dosage and administration | Research | Hepatitis C | Medicine | Cirrhosis | Genotype & phenotype | Hepatitis | Clinical trials | Infections | Interferon | Patients | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 1, pp. 22 - 31
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glomerulonephritis - chemically induced | Prealbumin - genetics | Humans | Middle Aged | Male | Amyloid Neuropathies, Familial - therapy | Injections, Subcutaneous | Oligonucleotides, Antisense - therapeutic use | Aged, 80 and over | Adult | Female | Prealbumin - analysis | Severity of Illness Index | Double-Blind Method | Amyloid Neuropathies, Familial - complications | Oligonucleotides, Antisense - adverse effects | Thrombocytopenia - chemically induced | Polyneuropathies - therapy | Disease Progression | Prealbumin - antagonists & inhibitors | Polyneuropathies - etiology | Least-Squares Analysis | Quality of Life | Aged | RNAi Therapeutics | Amyloid Neuropathies, Familial - blood | Treatment outcome | Care and treatment | Amyloidosis | Analysis | Quality of life | Glomerulonephritis | Thrombocytopenia | Cardiomyopathy | Diabetes mellitus | Transthyretin | Antisense oligonucleotides | Diabetic neuropathy | Neuropathy | Polyneuropathy | Patients | Proteins | Hospitals | Questionnaires | Amyloid | Diabetes | Mutation | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9973, pp. 1075 - 1086
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Hepacivirus - genetics | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Male | RNA, Viral - blood | Interferons - therapeutic use | Hepatitis C, Chronic - complications | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Ribavirin - administration & dosage | Treatment Failure | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Liver Cirrhosis - etiology | Drug Administration Schedule | Quinoxalines - administration & dosage | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Adolescent | Aged | Medical colleges | Protease inhibitors | Proteases | Clinical trials | Product development | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis | Ribavirin | Comparative studies | Hepatitis | Genotype & phenotype | Interferon | Drug therapy | Index Medicus | Abridged Index Medicus | Life Sciences | UNITED-STATES | SOFOSBUVIR | RIBAVIRIN | Klinisk medicin | SUSTAINED VIROLOGICAL RESPONSE | Medicine | Clinical Medicine | HCV NS5A INHIBITOR | TREATMENT-EXPERIENCED PATIENTS | DISEASE BURDEN | General & Internal | DOUBLE-BLIND | INTERFERON-ALPHA 2A | TREATMENT-NAIVE PATIENTS | PLUS
Journal Article
Nature (London), ISSN 0028-0836, 10/2019, Volume 574, Issue 7780, pp. 679 - 685
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biological Evolution | Viridiplantae - genetics | Transcriptome | Databases, Genetic | Genome, Plant | Phylogeny | Evolution, Molecular | Botanical research | Genetic aspects | Plants | Research | Natural history | Trees | Plants (botany) | Polyploidy | Gene families | Genomics | Genes | Terrestrial environments | Algae | Biological evolution | Discordance | Genomes | Gene sequencing | Species diversity | Ferns | Plant diversity | Phylogenetics | Evolution | Flowering | Flowers & plants | Bioinformatics | Species | Speciation | Aquatic ecosystems | Index Medicus | Molecular evolution | Adaptive radiation | Plant evolution | Phylogenomics
Journal Article
Journal of hepatology, ISSN 0168-8278, 2017, Volume 67, Issue 2, pp. 263 - 271
Gastroenterology and Hepatology | SURVEYOR | ABT-530 | Pangenotypic | D-alanine transaminase | Hepatitis C, chronic | Interferons | Direct-acting antiviral | Genotype | ABT-493 | Sustained virologic response | Liver cirrhosis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Pyrrolidines - administration & dosage | Pyrrolidines - adverse effects | Male | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Hepacivirus - drug effects | Drug Administration Schedule | Drug Resistance, Multiple, Viral - genetics | Quinoxalines - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polymorphism, Genetic | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Sulfonamides - administration & dosage | Alanine | Clinical trials | Chronic infection | Viruses | Proteinase inhibitors | Patients | Ribavirin | Hepatitis | Genotype & phenotype | Cirrhosis | Alanine transaminase | Interferon | Hepatitis C | Antiviral drugs | Genotypes | Index Medicus
Journal Article
Liver transplantation, ISSN 1527-6465, 10/2008, Volume 14, Issue S2, pp. S36 - S44
Gastroenterology & Hepatology | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Liver Neoplasms - virology | Recurrence | Reoperation | Liver Transplantation | Humans | Risk Factors | Graft Survival | Carcinoma, Hepatocellular - virology | Cholestasis - virology | Hepatitis C - surgery | Immunosuppression | Hepatitis C - complications | Hepatitis C - physiopathology | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2608 - 2617
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Young Adult | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Clinical trials | Usage | Genetic aspects | Research | Hepatitis C virus | Headache | Fatigue | Infections | Nausea | Patients | Ribavirin | Studies | Cirrhosis | Sleep disorders | Genotype & phenotype | Hepatitis | Hepatitis C | Drug therapy | Genotypes | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article